Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial
- PMID: 27377542
- DOI: 10.1016/S2213-8587(16)30102-4
Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial
Abstract
Background: The effects of testosterone on cognitive function in older men are incompletely understood. We aimed to establish the effects of long-term testosterone administration on multiple domains of cognitive function in older men with low or low-to-normal testosterone concentrations.
Methods: We did the randomised, double-blind, placebo-controlled, parallel-group TEAAM trial at three medical centres in Boston, Phoenix, and Los Angeles, USA. Men aged 60 years and older with low or low-to-normal testosterone concentrations (3·47-13·9 nmol/L, or free testosterone <173 pmol/L) were randomly assigned (1:1), via computer-generated randomisation, to receive either 7·5 g of 1% testosterone gel or placebo gel daily for 3 years. Randomisation was stratified by age (60-75 years vs >75 years) and study site. The testosterone dose was adjusted to achieve concentrations of 17·3-31·2 nmol/L. Participants and all study personnel were masked to treatment allocation. Multiple domains of cognitive function were assessed as prespecified secondary outcomes by use of standardised tests at baseline and months 6, 18, and 36. We did analyses by intention to treat (in men who had baseline assessments of cognitive function) and per protocol (restricted to participants who completed the study drug and had both baseline and 36 month assessments of cognitive function). The TEAAM trial is registered with ClinicalTrials.gov, number NCT00287586.
Findings: Between Sept 1, 2004, and Feb 12, 2009, we randomly assigned 308 participants to receive either testosterone (n=156) or placebo (n=152). 280 men had baseline cognitive assessments (n=140 per group). Mean follow-up time was 29·0 months (SD 11·5) in the testosterone group and 31·1 months (9·5) in the placebo group. The last participant completed the study on May 11, 2012. In the testosterone group, mean concentrations of serum total testosterone increased from 10·6 nmol/L (SD 2·2) to 19·7 nmol/L (9·2) and free testosterone concentrations increased from 222 pmol/L (62) to 364 pmol/L (222). In the placebo group, mean concentrations of serum total testosterone were 10·7 nmol/L (SD 2·3) at baseline and 11·1 nmol/L (3·2) post-intervention and free testosterone concentrations were 210 pmol/L (61) and 172 pmol/L (49), respectively. We recorded no between-group differences in changes in visuospatial ability (mean difference: Complex Figure Test -0·51, 95% CI -2·0 to 1·0), phonemic or category verbal fluency (phonemic fluency test 0·90, -1·3 to 3·1; categorical fluency test 1·1, -0·3 to 2·6), verbal memory (paragraph recall test 0·29, -1·2 to 1·8), manual dexterity (Grooved Pegboard Test 4·2, -1·3 to 9·7), and attention or executive function (Stroop Interference Test -2·6, -7·4 to 2·3) after adjustment for age, education, and baseline cognitive function. In both the intention-to-treat and per-protocol (n=86 per group) populations, changes in cognitive function scores were not related significantly to changes in total or free testosterone, or oestradiol concentrations.
Interpretation: Testosterone administration for 36 months in older men with low or low-to-normal testosterone concentrations did not improve cognitive function. Future long-term trials are needed to investigate the efficacy of testosterone replacement in patients with impaired cognition, such as people with Alzheimer's disease.
Funding: AbbVie Pharmaceuticals, Aurora Foundation, Boston Claude D Pepper Older Americans Independence Center, and Boston University's Clinical and Translational Science Institute.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Comment in
-
Testosterone and the brain: the power of a negative study.Lancet Diabetes Endocrinol. 2016 Aug;4(8):632-633. doi: 10.1016/S2213-8587(16)30142-5. Epub 2016 Jul 1. Lancet Diabetes Endocrinol. 2016. PMID: 27377543 No abstract available.
Similar articles
-
Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment.JAMA. 2017 Feb 21;317(7):717-727. doi: 10.1001/jama.2016.21044. JAMA. 2017. PMID: 28241356 Free PMC article. Clinical Trial.
-
Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial.JAMA. 2015 Aug 11;314(6):570-81. doi: 10.1001/jama.2015.8881. JAMA. 2015. PMID: 26262795 Clinical Trial.
-
Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.Lancet Neurol. 2017 May;16(5):377-389. doi: 10.1016/S1474-4422(17)30040-6. Epub 2017 Mar 27. Lancet Neurol. 2017. PMID: 28359749 Clinical Trial.
-
Dehydroepiandrosterone (DHEA) supplementation for cognitive function.Cochrane Database Syst Rev. 2001;(2):CD000304. doi: 10.1002/14651858.CD000304. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2007 Jul 18;(2):CD000304. doi: 10.1002/14651858.CD000304.pub2. PMID: 11405958 Updated. Review.
-
Folic acid with or without vitamin B12 for cognition and dementia.Cochrane Database Syst Rev. 2003;(4):CD004514. doi: 10.1002/14651858.CD004514. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2008 Oct 08;(4):CD004514. doi: 10.1002/14651858.CD004514.pub2. PMID: 14584018 Updated. Review.
Cited by
-
[Testosterone and Alzheimer's disease].Probl Endokrinol (Mosk). 2022 Jun 24;68(5):97-107. doi: 10.14341/probl13136. Probl Endokrinol (Mosk). 2022. PMID: 36337024 Free PMC article. Russian.
-
Testosterone, cognitive decline and dementia in ageing men.Rev Endocr Metab Disord. 2022 Dec;23(6):1243-1257. doi: 10.1007/s11154-022-09728-7. Epub 2022 May 28. Rev Endocr Metab Disord. 2022. PMID: 35633431 Free PMC article. Review.
-
Impact of Testosterone on Alzheimer's Disease.World J Mens Health. 2022 Apr;40(2):243-256. doi: 10.5534/wjmh.210175. Epub 2022 Jan 2. World J Mens Health. 2022. PMID: 35021306 Free PMC article. Review.
-
Cognitive Impairment in Long-Term Survivors of Testicular Cancer More Than 20 Years after Treatment.Cancers (Basel). 2021 Nov 12;13(22):5675. doi: 10.3390/cancers13225675. Cancers (Basel). 2021. PMID: 34830829 Free PMC article.
-
Utilization of Human Induced Pluripotent Stem Cells-Derived In vitro Models for the Future Study of Sex Differences in Alzheimer's Disease.Front Aging Neurosci. 2021 Nov 4;13:768948. doi: 10.3389/fnagi.2021.768948. eCollection 2021. Front Aging Neurosci. 2021. PMID: 34803659 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources